Kuruvilla, J. Et Al. 2021. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. The Lancet Oncology , vol.22, no.4 , 512-524.

Kuruvilla, J., Ramchandren, R., Santoro, A., Paszkiewicz-Kozik, E., Gasiorowski, R., Johnson, N. A., ... Fogliatto, L. M.(2021). Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. The Lancet Oncology , vol.22, no.4, 512-524.

Kuruvilla, John Et Al. "Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study," The Lancet Oncology , vol.22, no.4, 512-524, 2021

Kuruvilla, John Et Al. "Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study." The Lancet Oncology , vol.22, no.4, pp.512-524, 2021

Kuruvilla, J. Et Al. (2021) . "Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study." The Lancet Oncology , vol.22, no.4, pp.512-524.

@article{article, author={John Kuruvilla Et Al. }, title={Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study}, journal={The Lancet Oncology}, year=2021, pages={512-524} }